🔗 Permalink

Inventor profile of:

Michael Wade

City:

Chapel Hill, North Carolina

Country:

United States

Published Applications:

Last publication date:

2024-04-25

Top Assignees for applications by Michael Wade

The entities that hold a legal rights for patent applications filed by inventor Wade Michael:

United Therapeutics Corporation 23 Silver Spring, MD United States

Recent patent applications by Wade Michael

Michael Wade from Chapel Hill, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-04-25

US20240131078A1

Human necessities

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

#2 | 2024-03-28

US20240100003A1

Human necessities

Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

#3 | 2023-04-13

US20230112834A1

Human necessities

PARENTERAL FORMULATIONS OF TREPROSTINIL

#4 | 2022-03-03

US20220062210A1

Human necessities

Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

#5 | 2021-06-17

US20210177787A1

Human necessities

INHALATION FORMULATIONS OF TREPROSTINIL

#6 | 2021-02-04

US20210030812A1

Human necessities

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

#7 | 2020-07-23

US20200230089A1

Human necessities

INHALATION FORMULATIONS OF TREPROSTINIL

#8 | 2019-08-01

US20190231722A1

Human necessities

Inhalation formulations of treprostinil

#9 | 2019-05-30

US20190160032A1

Human necessities

Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

#10 | 2019-01-10

US20190008904A1

Human necessities

Treatment of pulmonary arterial hypertension with mesenchymal stem cells

#11 | 2018-10-04

US20180280445A1

Human necessities

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

#12 | 2018-02-15

US20180042876A1

Human necessities

Inhalation formulations of Treprostinil

#13 | 2015-09-03

US20150246078A1

Human necessities

Treatment of pulmonary arterial hypertension with mesenchymal stem cells

#14 | 2015-08-06

US20150216909A1

Human necessities

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

#15 | 2015-06-18

US20150164834A1

Human necessities

Parenteral formulations of treprostinil

#16 | 2015-01-01

US20150005374A1

Human necessities

Compounds and methods for delivery of prostacyclin analogs

#17 | 2014-07-10

US20140193379A1

Human necessities

Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

#18 | 2014-01-16

US20140018431A1

Human necessities

TREPROSTINIL TREATMENT FOR INTERSTITIAL LUNG DISEASE AND ASTHMA

#19 | 2013-04-18

US20130096200A1

Human necessities

TREPROSTINIL TREATMENT FOR INTERSTITIAL LUNG DISEASE AND ASTHMA

#20 | 2012-05-24

US20120129941A1

Human necessities

TREPROSTINIL TREATMENT FOR INTERSTITIAL LUNG DISEASE AND ASTHMA

#21 | 2011-04-21

US20110092599A1

Human necessities

Use of treprostinil to treat neuropathic diabetic foot ulcers

#22 | 2009-05-14

US20090124697A1

Human necessities

Inhalation formulations of treprostinil

#23 | 2008-11-13

US20080280986A1

Human necessities

TREPROSTINIL TREATMENT FOR INTERSTITIAL LUNG DISEASE AND ASTHMA

#24 | 2005-12-22

US20050282903A1

Human necessities

Use of Treprostinil to treat neuropathic diabetic foot ulcers

#25 | 2005-07-28

US20050165111A1

Human necessities

Use of treprostinil to treat and prevent ischemic lesions

#26 | 2005-07-28

US20050165110A1

Human necessities

Use of treprostinil to improve kidney functions

InventorID:

199156 ⎘